Keck Medical Center of USC has purchased IB Clinic for automatically generating IB’s quantitative parameter maps. The installation provides Keck Medical Center with a processing solution that allows for standardized brain tumor imaging across multiple sites and platforms for its patients.

Imaging Biometrics®, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI) and the recognized leader in quantitative imaging analysis for brain tumor diagnosis and treatment, today announces it has taken its suite of products online via Arterys’s industry-leading medical AI platform. The products include IB Neuro, the premier magnetic resonance (MR) imaging dynamic susceptibility contrast (DSC)

Elm Grove, WI, USA – Imaging BiometricsTM, LLC (IB), a subsidiary of IQ-AI Limited (LON:IQAI), in collaboration with the Barrow Neurological Institute (BNI), the Mayo Clinic (AZ), and the Medical College of Wisconsin (MCW), has received a $2.57 million, five-year grant award from the National Institutes of Health(NIH) – National Cancer Institute (NCI).

Imaging Biometrics, LLC, (IB), a wholly-owned subsidiary of IQ-AI and the recognized industry leader in quantitative imaging analysis for brain tumor diagnosis and treatment, is proud to announce its software applications for vascular mapping of tumors were featured in the top-award-winning article in the March 2020 issue of the American Journal of Neuroradiology (AJNR).

AI Metrics, LLC (Birmingham, AL), announced today that is has entered into a global distribution agreement with Imaging Biometrics, LLC, a subsidiary of IQ-AI Limited (LON:IQAI). The agreement grants IB non-exclusive global rights to market and distribute AI Metrics’ LSN image analysis product.

Imaging Biometrics®, LLC (“IB”), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that is has entered into a global distribution agreement with AI Metrics, LLC (Birmingham, AL).

Principal Investigator, Kathleen Schmainda, PhD, MCW professor of Biophysics, will leverage her foundational work in perfusion MRI technologies to more precisely identify brain tumor burden and provide earlier treatment response assessment over what is currently available. The grant’s objectives also include incorporating artificial intelligence capabilities for streamlined and automated processing.

Delta T1 on par with central reader analysis but offers substantial time and cost savings.